Ashley Yeo
Executive Editor, MTI; Medtech Editor, In Vivo

Ashley has reported on health care market issues with Citeline and legacy companies since 1988, initially as a linguist on the France and Germany desk and later becoming editor of three titles. Two publications are his current focus for written and multimedia (panel moderating and podcasts) content: In Vivo (global medtech market access); and Medtech Insight (regulation and policy content for the UK, European and Asia markets).
Latest From Ashley Yeo
German-Speaking European Associations Collaborate To Focus On Medtech’s Needs
Three central European industry associations have agreed to develop joint initiatives and form a collective voice with which to lobby decision-makers on medtech themes of mutual interest.
Macro Challenges Make Calls On Newly Resilient Medtechs
Global medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.
Solventum: The Identity Of 3M’s Health Care Spin-Off
3M’s health care company spin-off is expected to be launched in the first half of 2024 under the name Solventum.
Manufacturing Devices In The Rollercoaster UK Market
A scale-up strategy is the missing link in the UK devices industry, claims business research organization CPI. Own brand and contract medical manufacturer and packaging company Pennine Healthcare and longstanding medical device CDMO Renfrew Group International give their take on the environment for manufacturers and the opportunities for strengthening the industry base.
Innovation Adoption: ‘Medtech’s Ongoing Challenge Of The Day’
UK ministers are increasingly focusing on the need to improve uptake of new technologies in the National Health Service. Ambitious programs have been launched but implementing them effectively for lasting change in a delivery system under acute stress is a challenge of a different order.
Bringing Polygenics Into Cardiovascular Disease Diagnosis
GENinCode’s mission as a clinical-genetic diagnostic company is to apply a combination of polygenics, a proprietary bioinformatics platform and AI to risk-assess and prevent cardiovascular disease. The company set a UK precedent in being the first to have a CVD commercial polygenic test implemented in the NHS and keenly awaits another milestone, US 510k clearance in 2024.